Answers are grounded in this paper and cite their sources.
Narrative review examines how psyllium and glucomannan influence gut health in metabolic therapies, suggesting potential benefits.
Dietary fiber is an under-consumed nutritional substrate that supports gut microbial metabolism, intestinal barrier integrity, enteroendocrine signaling, and cardiometabolic regulation. Among dietary fibers, psyllium and glucomannan are clinically accessible viscous, gel-forming soluble fibers with distinct but complementary physicochemical profiles. This narrative review examines how these fibers act through luminal viscosity, nutrient diffusion, bile acid and cholesterol handling, short-chain fatty acid production, epithelial barrier support, enteroendocrine L-cell signaling, and low-grade metabolic inflammation. Psyllium has the strongest clinical support for stool normalization, glycemic modulation, and LDL cholesterol reduction, whereas glucomannan provides marked viscosity and water-holding capacity that may support satiety, lipid modulation, and weight-management strategies when appropriately hydrated and tolerated. We also discuss the emerging nutritional context of glucagon-like peptide-1 receptor agonist therapy, in which appetite suppression, reduced meal volume, delayed gastrointestinal transit, and constipation may reduce dietary fiber intake and fermentable substrate delivery to the colon. The pain- and mood-related implications are framed as hypothesis-generating extensions, because direct clinical evidence that psyllium or glucomannan improves these outcomes remains limited. A psyllium-centered, selectively glucomannan-supported strategy may help close the fiber gap and support bowel function, microbial metabolite signaling, and cardiometabolic stability during modern metabolic and weight-loss therapies.
No takes yet. Share an insight, caveat, or question.
Yoon et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: